A simple genetic stratification method for lower cost, more expedient clinical trials in early Alzheimer's disease: A preliminary study of tau PET and cognitive outcomes
Alzheimer's & Dementia · 2023
DOI: 10.1002/alz.12952 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2023. Verfasst von Xin Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of California, San Diego, California, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NINDS NIH HHS, National Institutes of Health.
Themen: Demenz
Abstract (Originalsprache)
Introduction
Identifying individuals who are most likely to accumulate tau and exhibit cognitive decline is critical for Alzheimer's disease (AD) clinical trials.
Methods
Participants ( N = 235) who were cognitively normal or with mild cognitive impairment from the Alzheimer's Disease Neuroimaging Initiative were stratified by a cutoff on the polygenic hazard score (PHS) at 65th percentile (above as high‐risk group and below as low‐risk group). We evaluated the associations between the PHS risk groups and tau positron emission tomography and cognitive decline, respectively. Power analyses estimated the sample size needed for clinical trials to detect differences in tau accumulation or cognitive change.
Results
The high‐risk group showed faster tau accumulation and cognitive decline. Clinical trials using the high‐risk group would require a fraction of the sample size as trials without this inclusion criterion.
Discussion
Incorporating a PHS inclusion criterion represents a low‐cost and accessible way to identify potential participants for AD clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of California, San Diego, California, USA.
- East China Normal University, Shanghai, China.
- University of California, Los Angeles, California, USA.
Förderung
- NIA NIH HHS
- NINDS NIH HHS
- National Institutes of Health
Zitieren
APA
Wang, X., Broce, I., Qiu, Y., Deters, K. D., Fan, C. C., Dale, A. M., Edland, S. D., Banks, S. J., & Alzheimer's Disease Neuroimaging Initiative (2023). A simple genetic stratification method for lower cost, more expedient clinical trials in early Alzheimer's disease: A preliminary study of tau PET and cognitive outcomes. Alzheimer's & Dementia. https://doi.org/10.1002/alz.12952
Vancouver
Wang X, Broce I, Qiu Y, Deters KD, Fan CC, Dale AM, et al. A simple genetic stratification method for lower cost, more expedient clinical trials in early Alzheimer's disease: A preliminary study of tau PET and cognitive outcomes. Alzheimer's & Dementia. 2023. doi:10.1002/alz.12952
BibTeX
@article{Wang2023,
author = {Wang, Xin and Broce, Iris and Qiu, Yuqi and Deters, Kacie D and Fan, Chun Chieh and Dale, Anders M and Edland, Steven D and Banks, Sarah J and Alzheimer's Disease Neuroimaging Initiative, Alzheimer's Disease Neuroimaging Initiative},
title = {A simple genetic stratification method for lower cost, more expedient clinical trials in early Alzheimer's disease: A preliminary study of tau PET and cognitive outcomes},
journal = {Alzheimer's & Dementia},
year = {2023},
doi = {10.1002/alz.12952}
}
EUVIMED